Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...

UBS initiated coverage of Celldex (CLDX) with a Buy rating and $44 price target The firm says KIT inhibition is “differentiated in the ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Bio (NASDAQ:THRD) stock rating was downgraded by Morgan Stanley (NYSE:MS) from Overweight to Equalweight, accompanied by a significant reduction in the price target to $5.00 from the previous $20.00.

The company explained that, in a comparison of the effects of YH35324 and Xolair in patients with chronic spontaneous urticaria (CSU), patients administered YH35324 showed significantly better symptom ...

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

What if the food you eat and the way you handle stress could make a real difference for your chronic spontaneous urticaria?